Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Europe's DRG systems will hit companies in France, Germany and the UK

This article was originally published in Clinica

Executive Summary

Based on their product ranges Coloplast, Fresenius, Smith & Nephew and Getinge are among the medical technology companies that will be affected most by the phasing-in of DRG-based systems in France, Germany and the UK. That is the view of Merrill Lynch research analyst, Michael Jungling, based on an analysis of DRG issues for all 16 of its medtech portfolio companies, as detailed at IBC Life Sciences reimbursement meeting in Brussels, at the end of November.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel